৳ ০.০০
আপনার সব স্বাস্থ্যসেবার সমাধান — এখন এক জায়গাতেই
১০৬৫৭
info@shukhee.com
টেলিকম ভবন, ৫৩/১, বক্স নগর, ঢাকা-১২১৬
৳ ০.০০
১০৬৫৭
info@shukhee.com
টেলিকম ভবন, ৫৩/১, বক্স নগর, ঢাকা-১২১৬


Products
Payment
Delivery
Roxatat (Roxadustat) is indicated for the treatment of symptomatic anemia associated with chronic kidney disease (CKD) in adult patients.
Roxatat is a first-in-class, orally administered HIF-PH (Hypoxia-Inducible Factor Prolyl Hydroxylase) inhibitor that promotes erythropoiesis by increasing endogenous erythropoietin (EPO) production. It also improves iron regulation and counteracts the inflammation-induced suppression of hemoglobin synthesis and red blood cell production by reducing hepcidin levels.
Roxadustat is an orally bioavailable hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) with anti-anemic activity.
After administration, Roxadustat binds to and inhibits HIF-PH, an enzyme responsible for degradation of HIF transcription factors under normal oxygen conditions. Inhibition of HIF-PH prevents HIF degradation and promotes HIF activity.
Increased HIF activity results in:
HIF regulates genes involved in adaptation to low oxygen conditions, including genes required for erythropoiesis and iron metabolism.
Clinical studies have demonstrated that Roxadustat:
Roxadustat reversibly and potently inhibits HIF prolyl hydroxylase enzymes, reducing degradation of HIF-α and promoting HIF-mediated gene transcription.
This leads to activation of genes involved in:
In patients with CKD-associated anemia, Roxadustat:
Additionally, cholesterol levels are significantly reduced from baseline irrespective of concomitant treatment with statins or other lipid-lowering agents.
Roxadustat should be taken orally three times weekly, ensuring that doses are not taken on consecutive days.
Treatment should be individualized to achieve and maintain target hemoglobin levels of 10–12 g/dL.
Adults:
Recommended starting dose according to body weight:
Adults:
Subsequent dosage should be adjusted according to the patient's clinical response and condition.
When adjustment is necessary, increase or decrease the dose according to the approved dose-adjustment schedule.
After a dose change:
20 mg → 40 mg → 50 mg → 70 mg → 100 mg → 150 mg → 200 mg → 250 mg → 300 mg → 400 mg (for dialysis-dependent CKD patients only)
Roxadustat tablets may be taken:
Risk:
Recommendation: Take Roxatat at least 1 hour after phosphate binders or products containing multivalent cations.
Gemfibrozil: CYP2C8 and OATP1B1 inhibitor
Probenecid: UGT and DAT1/DAT3 inhibitor
Risk:
Recommendation: Adjust Roxatat dosage based on hemoglobin monitoring and dose-adjustment guidelines.
Examples:
Risk:
Recommendation: Monitor hemoglobin and adjust Roxatat dosage as clinically appropriate.
Common adverse reactions include:






N/A
N/A





